Vasopressin

Vasopressin — ADMETatlas

Structure and chemistry interpretation

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

CYFQNCPRG

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references2 references

Structure reference·

3D coordinates·Exact PDB matchexperimental

Exact PDB match·reference selected·length 9 aa·confidence experimental

Link	Method	Confidence	Match
Open

Covalent topology & modifications1 signal

Feature	Positions	Interpretation	Link
Disulfide	1-6	2.02 A SG-SG	Open

Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.

5. Exposure / Absorption

What evidence describes systemic exposure or absorption?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Bioavailability Cmax AUC

Bioavailability, AUC, Cmax, and Tmax evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	~ 0 %	Comparable	PepTherDia curated product PK field	Route: ORAL · 3 · Vasopressin (or Argipressin) · exact product name match · exact or normalized match	Open

AUC

Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.

6. Distribution / Barrier

What is known about distribution, binding, permeability, or barrier crossing?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Plasma protein binding BBB penetration Vd

Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	140 mL/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vasopressin· 12.3 Pharmacokinetics · volume of distribution single · The volume of distri...	Open

Plasma protein binding

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.

7. Metabolic & Proteolytic Stability

How stable is the peptide in biological matrices or protease systems?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Serum/plasma stability

Serum/plasma stability and protease stability evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability3 measurements · 1 comparable · 2 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	1.3 minutes 78 seconds	Comparable	Radioimmunoassay · Rabbit plasma	Dose/window: Endogenously administered · Proteases from Rabbit plasma · in vivo	Open
2	Observation 5.4(lower phase)	Reported	Radioimmunoassay · Rabbit plasma	Dose/window: Exogenously administered · Proteases from Rabbit plasma · in vivo	Open
3	Observation 0.9(fast component)	Reported	Radioimmunoassay · Rabbit plasma	Dose/window: Exogenously administered · Proteases from Rabbit plasma · in vivo	Open

Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.

8. Excretion / Persistence

What evidence describes clearance or persistence?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Half Life Clearance

Clearance and half-life evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance2 measurements · 2 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	range 9-25 mL/min/kg	Comparable	curated therapeutic product PK entry	Route: Official current-label support for vasopressin clearance in vasodilatory shock patients.	Open
2	9-25 mL/min/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Vasopressin· 12.3 Pharmacokinetics · clearance range direct · Elimination At infusion rat...	Open

Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

8 measurements

Distribution / Barrier

16 measurements

Metabolic & Proteolytic Stability

3 measurements

Excretion / Persistence

12 measurements

Toxicity / Safety

0 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Blood Brain Barrier Penetration

Half Life

Max Concentration

Area Under Curve

Serum Plasma Stability

Clearance

Plasma Protein Binding

Bioavailability

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Clinical / product

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Half Life	1 minutes 60 seconds	Comparable	Radioimmunoassay · mouse · Insulin-treated IRAP+/+ mice	Time: 1,2 and 3 minutes · Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Protease: Mice blood proteases · in vivo	Open
2	Excretion / Persistence Persistence	Half Life	approx 1.5 minutes approx 90 seconds	Comparable	Radioimmunoassay · mouse · Saline treated IRAP+/+ mice	Time: 1,2 and 3 minutes · Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Protease: Mice blood proteases · in vivo	Open
3	Excretion / Persistence Persistence	Half Life	Observation 80 (elimination t1/2 after 6-24h of i/v injection)	Contextual	Radioimmunoassay, HPLC · (Dose i/v injected)urine of women with endometriosis	Dose/window: 500 μg/kg · Protease: Proteases from urine of women with endometriosis · in vivo	Open
4	Excretion / Persistence Persistence	Half Life	Observation 8.90 ±0.37 (slow phase)	Contextual	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31261	Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Dose/window: 15 μCi (555 kBq) · Protease: Rat blood proteases · in vivo	Open
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation 5.4(lower phase)	Contextual	Radioimmunoassay · Rabbit plasma	Dose/window: Exogenously administered · Protease: Proteases from Rabbit plasma · in vivo	Open
6	Excretion / Persistence Persistence	Half Life	3 minutes 180 seconds	Comparable	Radioimmunoassay · mouse · Insulin-treated IRAP-/- mice.	Time: 1,2 and 3 minutes · Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Protease: Mice blood proteases · in vivo	Open
7	Excretion / Persistence Persistence	Half Life	Observation 1.00 ±0.15 (fast phase)	Contextual	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31260	Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Dose/window: 15 μCi (555 kBq) · Protease: Rat blood proteases · in vivo	Open
8	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1.3 minutes 78 seconds	Comparable	Radioimmunoassay · Rabbit plasma	Dose/window: Endogenously administered · Protease: Proteases from Rabbit plasma · in vivo	Open
9	Excretion / Persistence Persistence	Half Life	Observation 1.06 ±0.19 (fast phase)	Contextual	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats	Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Dose/window: 15 μCi (555 kBq) · Protease: Rat blood proteases · in vivo	Open
10	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation 0.9(fast component)	Contextual	Radioimmunoassay · Rabbit plasma	Dose/window: Exogenously administered · Protease: Proteases from Rabbit plasma · in vivo	Open

1–10 / 39

Identity & reference map

Summary17 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 17
Measurements: 39
ATL peptide ID: ATLPC0018357

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

27 / 27

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 27

Different notation

Reported notation does not resolve to the current display sequence.

0 / 27

Reference map17 of 17 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
PubMed 17684103 Open	Persistence Half Life	No reported alias CYFQNCPRGexact	7 identity 7 evidence
PubMed 2521208 Open	PersistenceStability Half Life, Serum Plasma Stability	No reported alias CYFQNCPRGexact	4 identity 4 evidence
Reference link Open	Distribution Blood Brain Barrier Penetration	No reported alias CYFQNCPRGexact	4 identity 4 evidence
DOI 10.1038/s41598-024-74188-9 Open	Exposure Area Under Curve, Max Concentration	No reported alias	0 identity 7 evidence
Reference link Open	Distribution Blood Brain Barrier Penetration	No reported alias CYFQNCPRGexact	2 identity 2 evidence
Reference link Open	DistributionPersistence Clearance, Plasma Protein Binding, Volume Of Distribution	No reported alias	0 identity 3 evidence
PubMed 7418787 Open	Persistence Half Life	No reported alias CYFQNCPRGexact	1 identity 1 evidence
PubMed 22186872 Open	Persistence Half Life	No reported alias CYFQNCPRGexact	1 identity 1 evidence
Reference link Open	Persistence Clearance	No reported alias CYFQNCPRGexact	1 identity 1 evidence
Reference link Open	Distribution Blood Brain Barrier Penetration	No reported alias CYFQNCPRGexact	1 identity 1 evidence

1–10 / 17

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0018357
Identity type: canonical sequence
ADMET endpoints: 9
Measurements: 39
Reference groups: 17
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0018357

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0018357' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

#	Value	Evidence layer	Assay / model	Condition	Reference
1	7264 pg*min/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: endotracheal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open
2	675 pg*min/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open
3	2012 pg*min/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open

Cmax4 measurements · 4 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	958 pg/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: endotracheal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open
2	384 pg/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open
3	399 pg/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: intranasal · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open
4	2253 pg/mL	Comparable	ELISA plasma concentration assay; MATLAB SimBiology noncompartmental analysis; manual extraction from article pharmacokinetic parameters text · neonatal piglet · plasma	Route: intravenous · Dose/window: baseline to 10 min post-dose serial arterial sampling	Open

#	Value	Evidence layer	Assay / model	Condition	Reference
1	1 %	Comparable	PepTherDia curated product PK field · plasma protein	Route: IM, SC, IV, NASAL · 3 · Vasopressin (or Argipressin) · exact product name match · exact or normalized match	Open
2	Observation Distribution Vasopressin does not appear to bind plasma protein.	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Vasopressin· 12.3 Pharmacokinetics · plasma binding no apparent binding text · Distributi...	Open

BBB penetration13 measurements · 6 comparable · 7 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	4.0 x 10^-5 cm/s	Comparable	(Co)-culture · blood-brain barrier	Pe · non saturable	Open
2	0.00827 mL/g	Comparable	Capillary depletion · blood-brain barrier	CD (parenchyma/serum) · saturable	Open
3	0.00237 mL/g/min	Comparable	In situ brain perfusion · blood-brain barrier	Kin · NA	Open
4	0.0042 mL/g	Comparable	In situ brain perfusion · blood-brain barrier	Vi · NA	Open
5	148 ratio	Comparable	Intracarotid injection · blood-brain barrier	Blood/brain ratio · NA	Open
6	1.1 x 10^-4 mL/g/min	Comparable	Intravenous injection (multiple time regression) · blood-brain barrier	Kin · NA	Open
7	142	Reported	NA · NA · NA · blood-brain barrier	Route: Intracarotid injection · Permeability	Open
8	148	Reported	NA · NA · NA · blood-brain barrier	Route: Intracarotid injection · Permeability	Open
9	Observation raw_value: 0.0042 ml/g; result: 0.0042 ml/g; transport_type: Permeability	Reported	NA · NA · NA · blood-brain barrier	Route: in situ brain perfusion · Permeability	Open
10	Observation raw_value: 0.00237 mL/(g x min); result: 0.00237 mL/(g x min); transport_type: Permeability	Reported	NA · NA · NA · blood-brain barrier	Route: in situ brain perfusion · Permeability	Open

1–10 / 13

#	Value	Evidence layer	Assay / model	Condition	Reference
1	> 7 days > 604800 seconds	Comparable	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro	Open
2	3 minutes 180 seconds	Comparable	Radioimmunoassay · mouse · Insulin-treated IRAP-/- mice.	Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo	Open
3	1 minutes 60 seconds	Comparable	Radioimmunoassay · mouse · Insulin-treated IRAP+/+ mice	Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo	Open
4	approx 1.5 minutes approx 90 seconds	Comparable	Radioimmunoassay · mouse · Saline treated IRAP+/+ mice	Dose/window: 50 or 0.4 pmol of vasopressin with 33 kBq · Time: 1,2 and 3 minutes · Mice blood proteases · in vivo	Open
5	Observation 47.4 (t1/2 of specific radioactivity)	Reported	Liquid scintillation spectrometer · Weakly acidic solution (pH 4.0, acetic acid)	Dose/window: 0.2 mg · in vitro	Open
6	Observation 1.06 ±0.19 (fast phase)	Reported	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats	Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo	Open
7	Observation 5.96 ±0.58 (slow phase)	Reported	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats	Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo	Open
8	Observation 1.00 ±0.15 (fast phase)	Reported	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31260	Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo	Open
9	Observation 8.90 ±0.37 (slow phase)	Reported	Radioimmunoassay · rat · Female homozygous Brattleboro rats and male Wistar rats along with OPC-31261	Dose/window: 15 μCi (555 kBq) · Time: 20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min · Rat blood proteases · in vivo	Open
10	Observation 80 (elimination t1/2 after 6-24h of i/v injection)	Reported	Radioimmunoassay, HPLC · (Dose i/v injected)urine of women with endometriosis	Dose/window: 500 μg/kg · Proteases from urine of women with endometriosis · in vivo	Open

Vasopressin

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Exposure / Absorption

Evidence summary

6. Distribution / Barrier

Evidence summary

7. Metabolic & Proteolytic Stability

Evidence summary

8. Excretion / Persistence

Evidence summary

9. Evidence landscape

Evidence landscape and measurement index

10. Identity & reference map

Identity & reference map

11. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record